Amgen Inc.

Novartis successfully concluded negotiations with the pan-Canadian Pharmaceutical Alliance for public reimbursement of Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa.

Novartis announced that its Phase III GCAptAIN study of Cosentyx (secukinumab) failed to achieve sustained remission at Week 52 in adults with newly diagnosed or relapsing giant cell arteritis.

The U.S. Court of Appeals for the Federal Circuit's decision in Xencor Inc. case provides drugmakers with a new strategy to challenge patents by focusing on inadequate written descriptions in Jepson claims.

The U.S. gene therapy market is expected to grow from $4.37 billion in 2025 to $22.23 billion by 2034, driven by increasing investments, rising prevalence of chronic diseases, and integration of advanced technologies.

The weight loss drugs market is predicted to grow rapidly, with analysts at SNS Insider forecasting a 43.73% CAGR through 2032, driven by rising obesity rates.

The FDA has approved blinatumomab for adult and pediatric patients with CD19-positive, Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase.

Non-small cell lung cancer affects approximately 2.1 million people globally, with the Asia-Pacific region showing the highest incidence and leading clinical trial activities.

Novartis announced that its Phase III GCAptAIN study of Cosentyx (secukinumab) failed to meet the primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing giant cell arteritis.